Abstract
The clinical course of oral mucosal inflammatory and ulcerative diseases can range from being self-limiting to potentially life threatening. Effective management of these diseases is essential to improve overall health and quality of life. Pharmacologic therapy plays an important role in the efficient treatment of oral mucosal inflammatory and ulcerative diseases. Therapeutic choices should be patient centered and evidenced based on the diagnosis of the disorder. Treatment regimens depend on the severity and extent of the oral mucosal involvement. Clinician should select the appropriate treatment, weighing the risks and benefits of different treatment approaches. Antimicrobial agents and immunosuppressive drugs such as corticosteroid are the two major classes of drugs used in the management of oral ulcerative stomatitis. These drugs should not be used empirically without obtaining an accurate diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Further Reading
Vigneswaran N, Muller S (2019) Pharmacologic management of oral mucosal inflammatory and ulcerative diseases. In: Jeske AH (ed) Contemporary dental pharmacology; evidenced-based considerations. Springer Nature, Switzerland, pp 91–108
Magel GD, Haitz KA, Lapolla WJ, DiGiorgio CM, Mendoza CM, Tyring SK (2013) Systemic antiviral agents. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy. Saunders/Elsevier, Philadelphia, pp 121–134
Radulescu M (2016) The pharmacologic management of common lesions of the oral cavity. Dent Clin N Am 60(2):407–420
Gupta AK (2013) Systemic antifungal agents. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy. Saunders/Elsevier, Philadelphia, pp 98–120
Taylor J et al (2015) World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol 120(2):161–171
Didona D, Maglie R, Eming R, Hertl M (2019) Pemphigus: current and future therapeutic strategies. Front Immunol 2019(10):1418
Funding
This research was supported by the National Institute of Dental and Craniofacial Research (Grant R01DE024392).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Vigneswaran, N., Muller, S. Pharmacologic treatment of oral mucosal inflammatory and ulcerative diseases. Clin Dent Rev 4, 18 (2020). https://doi.org/10.1007/s41894-020-00077-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s41894-020-00077-9